SCShanze Chen

Shanze Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shanze Chen has a total of 127 co-authors. Here are the top co-authors by number of shared publications:

  • Lingwei Wang

    Department of Respiratory Medicine and Intensive Care Unit, Shenzhen Institute of Respiratory Diseases, Shenzhen People’s Hospital (The Second School of Clinical Medicine of Jinan University and The First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, China

    9 shared publications
  • Rongchang Chen

    Department of Pulmonary and Critical Care Medicine, Shenzhen Key Laboratory of Respiratory Diseases, Shenzhen Clinical Research Center for Respiratory Disease, Shenzhen Institute of Respiratory Diseases, The First Affiliated Hospital, The Second Clinical Medical College, Shenzhen People’s Hospital, Southern University of Science and Technology, Jinan University, Shenzhen, China

    5 shared publications
  • Ruifang Liang

    Department of Respiratory Medicine and Intensive Care Unit, Shenzhen Institute of Respiratory Diseases, Shenzhen People’s Hospital (The Second School of Clinical Medicine of Jinan University and The First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, China

    5 shared publications
  • Haizhao Xu

    Department of Respiratory Medicine and Intensive Care Unit, Shenzhen Institute of Respiratory Diseases, Shenzhen People’s Hospital (The Second School of Clinical Medicine of Jinan University and The First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, China

    4 shared publications
  • Jinyong Wang

    Department of Pulmonary and Critical Care Medicine, Shenzhen Institute of Respiratory Diseases, The First Affiliated Hospital (Shenzhen People’s Hospital) and School of Medicine, Southern University of Science and Technology, Shenzhen, China

    4 shared publications
  • Laibin Ren

    Department of Pulmonary and Critical Care Medicine, Shenzhen Institute of Respiratory Diseases The First Affiliated Hospital (Shenzhen People's Hospital) and School of Medicine, Southern University of Science and Technology Shenzhen 518055 China

    4 shared publications

Latest Publications

  • Open Access

    Ciliary-enriched and keratinization-dominant endotypes drive molecular heterogeneity in AECOPD

    by Jiacheng Zhong, Zhen Wang, Hanting Li, Kai Yang, Yu Meng, Shanze Chen, Lingwei Wang

  • Open Access

    Towards scalable DNA data storage with DNA-SaM codec system

    by Yu Wang, Jiaxin Xu, Yang Wang, Ziang Nie, Jiaquan Huang, Mingen Li, Yaxin Wu, Yixuan Sun, Shanze Chen, Hui Mei, et al.

    The exponential growth of global data volume is driving an urgent need for novel storage medium. Deoxyribonucleic Acid (DNA), nature’s genetic repository, presents a transformative solution with data storage density and lifespan orders of magnitude higher than conventional media. However, scaling DNA storage has been hindered by the complexity of codec algorithms, the generation of biochemically problematic sequences, and the absence of robust architecture for large-scale data. We present DNA-SaM, a system integrating highly efficient encoding, stringent biochemical constraint checks, and a storage unit distribution paradigm facilitated by a two-tiered indexing architecture. DNA-SaM demonstrates linear encoding time complexity and substantially reduced encoding time compared with representative approaches by in silico analysis. Critically, it proactively excludes sequences such as homopolymer runs, tandem repeats, and potential promoter motifs that could interfere with downstream biochemical processes, showing improved compatibility with in vitro and in vivo applications. It is further validated by practical data storage both in vitro and in vivo with a 100% success rate. On the basis of its encoding scheme and sequence design space, DNA-SaM could theoretically store data exceeding 270 petabytes (PB), marking an advancement in the scalability of DNA-based data storage.

  • Open Access

    Single-cell multiomics uncovers an endothelial mechanosensitive PIEZO1-IL-33 axis driving pulmonary fibrosis

    by Lanlan Zhang, Xuezhen Gui, Ruijie Hou, Liping Jia, Shu Xia, Xin Zhang, Yingyun Fu, Qian-Fang Meng, Qun Luo, Xing Shi, et al.

    Pulmonary fibrosis represents a progressive interstitial lung disease marked by excessive extracellular matrix deposition and architectural distortion. Vascular endothelial cells critically contribute to fibrogenesis through paracrine secretion of pro-fibrotic mediators, yet their mechanobiological regulation remains elusive. Using integrated single-cell multi-omics profiling of human pulmonary fibrosis specimens and experimental fibrosis models induced by bleomycin or silica, we identify mechanosensitive Piezo1 upregulation in Endothelial cells as a hallmark of fibrotic progression. Endothelial-specific Piezo1 knockout significantly attenuates Bleomycin-induced fibrotic remodeling in male mice, establishing its pathogenic necessity. Mechanistically, PIEZO1 activation promotes pulmonary fibrosis development via CAPN2-mediated STAT3 phosphorylation, which may regulate the secretion of the pro-fibrotic molecule interleukin-33. These findings suggest that the endothelial PIEZO1-CAPN2-STAT3-IL33 axis is a potential therapeutic target for PF intervention.


  • Open Access

    Highly Secure In Vivo DNA Data Storage Driven by Genomic Dynamics

    by Jiaxin Xu, Yu Wang, Haibo Zhou, Mingen Li, Yang Wang, Lingwei Wang, Hui Mei, Junbiao Dai, Shanze Chen, Xiaoluo Huang

    DNA is a promising medium for next‐generation data storage because of ultrahigh information density and stability. DNA storage within living organisms presents further advantages, such as self‐replication, compactness, and concealment. Early efforts primarily developed predetermined methods for encoding and decoding data using in vivo DNA sequences. However, these methods may pose a security risk while opening a clear channel for potential data access and breaches. To address these challenges, we propose a unified paradigm, integrated computational–biological programming (ICBP), by exploiting the intrinsic digital characteristics within computational and microbial systems. ICBP involves the construction of dynamic code tables from gene regulatory networks or complete genomes across diverse species, expanding the key space by more than 100 orders of magnitude compared with existing methods. The encryption algorithm in ICBP benefits from DNA encoding, computing, and computational operations, leading to superior encryption quality and resistance to brute force and statistical attacks. Furthermore, we demonstrated the practical utility of ICBP via the successful encryption, microbial storage, and decryption of digital files within living systems, achieving 100% data recovery after 100 generations of replication. By combining computational logic with the biological complexities of living systems, the ICBP offers a transformative strategy for secure DNA data storage.

  • D-Mannose-Modified M2 Macrophage Membrane-Derived Decoy Nanovesicles for Synergistic Immunotherapy of Asthma

    by Shukun Zhao, Qiong Jiang, Ling Yu, Quan Liu, Zi Chen, Danting Zhan, Shuyu Chen, Yuqiong Yang, Jiacheng Zhong, Bingxin Guo, et al.

    Eosinophilic asthma is a chronic inflammatory disease driven by Type 2 immune cells and cytokines. While cytokine-based immunotherapies have shown promising efficacy in asthma treatment, current approaches often fail to simultaneously target multiple cytokines. In this study, we present nanodecoys derived from the cellular membranes of M2 macrophages, which exhibit a high density of cytokine receptors, enabling efficient sequestration of multiple Type 2 cytokines. This mechanism significantly alleviates OVA-induced eosinophilic asthma inflammation in mice. To enhance therapeutic efficacy, D-mannose glycans, a potential immunoregulatory molecule for asthma, were modified onto the surface of the nanovesicles. This modification facilitates the phagocytic clearance of absorbed cytokines by targeting the mannose receptor (CD206). Consequently, the mannose-modified nanovesicles exhibit synergistic immunosuppressive effects on asthmatic inflammation by inhibiting M2 macrophage polarization, CD4+ T cell Th2 polarization, and eosinophil activation, as revealed by single-cell RNA sequencing and in vitro analyses. In summary, this study presents a safe and effective nanotechnology-based immunotherapy for asthma and potentially other Type 2 inflammatory diseases.


  • SERS-based lateral flow immunoassay for rapid and sensitive sensing of nucleocapsid protein toward SARS-CoV-2 screening in clinical samples

    by Weixia Zhi, Lingwei Wang, Li Dai, Jing Xu, Tingting He, Xiangxin Zong, Jun Xu, Huaihong Cai, Jiang Pi, Pinghua Sun, et al.


  • Open Access

    Targeting BRD4 ameliorates experimental emphysema by disrupting super-enhancer in polarized alveolar macrophage

    by Difei Li, Xing Shi, Yuqiong Yang, Yao Deng, Dandan Chen, Shuyu Chen, Jinyong Wang, Guanxi Wen, Zhenyu Liang, Fengyan Wang, et al.

    Chronic obstructive pulmonary disease (COPD) is a progressive chronic lung disease characterized by chronic airway inflammation and emphysema. Macrophage polarization plays an important role in COPD pathogenesis by secreting inflammatory mediators. Bromodomain-containing protein 4 (BRD4), an epigenetic reader that specifically binds to histones, plays a crucial role in inflammatory diseases by regulating macrophage polarization. Herein, we attempted to examine the hypothesis that modulating alveolar macrophage polarization via BRD4 inhibitors might has a potential for COPD treatment. We firstly analyzed BRD4 expression and its correlation with clinical parameters and macrophage polarization markers in sputum transcriptomes from 94 COPD patients and 36 healthy individuals. In vivo, BRD4 inhibitor JQ1 and degrader ARV-825 were intraperitoneally administrated into emphysema mice to assess their effects on lung emphysema and inflammation. In vitro, RNA-seq and CUT&Tag assay of BRD4 and H3K27ac were applied for elucidating how BRD4 regulates macrophage polarization. We found an increased expression of BRD4 in the induced sputum from patients with COPD and unveiled a strong correlation between BRD4 expression and clinical parameters as well as macrophage polarization. Subsequently, BRD4 inhibitor JQ1 and degrader ARV-825 significantly mitigated emphysema and airway inflammation along with better protection of lung function in mice. BRD4 inhibition also suppressed both M1 and M2 alveolar macrophage polarization. The CUT&Tag assay of BRD4 and H3K27ac, revealed that BRD4 inhibition disrupted the super-enhancers (SEs) of IRF4 (a crucial transcription factor for M2 macrophage), and subsequently affected the expression of matrix metalloproteinase 12 (MMP12) which is vital for emphysema development. This study suggested that downregulation of BRD4 might suppress airway inflammation and emphysema through disrupting the SEs of IRF4 and alveolar macrophages polarization, which might be a potential target of therapeutic intervention in COPD. A diagram of the mechanism by which BRD4 mediated super-enhancer of IRF4 in M2 AMs. Graphic illustration showed targeting BRD4 in M2 polarized AMs lead to the downregulation of MMP12 expression, resulting in the amelioration of experimental emphysema by disrupting the super-enhancer of IRF4.


  • Open Access

    Targeting Immunoproteasome in Polarized Macrophages Ameliorates Experimental Emphysema Via Activating NRF1/2‐P62 Axis and Suppressing IRF4 Transcription

    by Bingxin Guo, Xing Shi, Qiong Jiang, Yuanwei Pan, Yuqiong Yang, Yuanyuan Liu, Shuyu Chen, Wenjiao Zhu, Laibin Ren, Ruifang Liang, et al.

    Chronic obstructive pulmonary disease (COPD) stands as the prevailing chronic airway ailment, characterized by chronic bronchitis and emphysema. Current medications fall short in treatment of these diseases, underscoring the urgent need for effective therapy. Prior research indicated immunoproteasome inhibition alleviated various inflammatory diseases by modulating immune cell functions. However, its therapeutic potential in COPD remains largely unexplored. Here, an elevated expression of immunoproteasome subunits LMP2 and LMP7 in the macrophages isolated from mouse with LPS/Elastase‐induced emphysema and polarized macrophages in vitro is observed. Subsequently, intranasal administration of the immunoproteasome‐specific inhibitor ONX‐0914 significantly mitigated COPD‐associated airway inflammation and improved lung function in mice by suppressing macrophage polarization. Additionally, ONX‐0914 capsulated in PLGA nanoparticles exhibited more pronounced therapeutic effect on COPD than naked ONX‐0914 by targeting immunoproteasome in polarized macrophages. Mechanistically, ONX‐0914 activated autophagy and endoplasmic reticulum (ER) stress are not attribute to the ONX‐0914 mediated suppression of macrophage polarization. Intriguingly, ONX‐0914 inhibited M1 polarization through the nuclear factor erythroid 2‐related factor‐1 (NRF1) and NRF2‐P62 axis, while the suppression of M2 polarization is regulated by inhibiting the transcription of interferon regulatory factor 4 (IRF4). In summary, the findings suggest that targeting immunoproteasome in macrophages holds promise as a therapeutic strategy for COPD.


  • Open Access

    Single-cell multiomics reveals endothelial mechanosensitive PIEZO1 coupling IL-33 regulates the development of pulmonary fibrosis

    by Shanze Chen, Lanlan Zhang, Xin Zhang, Xuezhen Gui, Shu Xia, Yingyun Fu, Qian-Fang Meng, Qun Luo, Xing Shi, Bingxin Guo, et al.

    Pulmonary fibrosis (PF) is a lethal lung disease characterized by aberrant lung scarring. Vascular endothelial cells (VECs), which activate fibroblasts through secreting pro-fibrotic molecules, are vital for the PF development. However, the regulatory mechanisms are not fully understood. Here, by employing single-cell multiomics to analyze samples from PF patients and bleomycin (BLM) and SiO2-induced PF mouse models, we discovered that increased mechanical force and mechanosensitive PIEZO1 on VECs are closely associated with PF development, Subsequently, EC-specific deletion of PIEZO1 significantly reduced BLM-induced mouse PF, thereby further validated the critical role of endothelial PIEZO1 in PF. Mechanistically, PIEZO1 activation couples with a pro-fibrotic molecule interleukin-33 (IL-33) to drive the PF development via calpain-2 (CAPN2)-signal transducer and activator of transcription 3 (STAT3) axis. Additionally, PIEZO1 antagonist GsMTx4 effectively alleviated fibrotic outcome, while agonist YODA1 exacerbated the results in mouse model. Our findings reveals the therapeutic potential of mechanosensitive pathways for PF.

  • Open Access

    “Multi-layer” encryption of medical data in DNA for highly-secure storage

    by Jiaxin Xu, Yu Wang, Xue Chen, Lingwei Wang, Haibo Zhou, Hui Mei, Shanze Chen, Xiaoluo Huang